来源:市场资讯(来源:求实药社)近日,港股创新药IPO板块传来了一则好消息,劲方医药已经通过了聆讯阶段,即将正式上市,于大而言,这是港股18A闸门扩大的又一标志,于小而言,这也标志着劲方医药迈过了一个里程碑,迈入了一个新阶段。在新股发行阶段,它也被资金抢得火热。那么劲方医药,这家在KRAS领域深耕的药企,也确实值得我们去仔细拆解。它的天花板是否高,下限是否稳健呢?01KRAS突变与市场劲方医药的...
Source Link来源:市场资讯(来源:求实药社)近日,港股创新药IPO板块传来了一则好消息,劲方医药已经通过了聆讯阶段,即将正式上市,于大而言,这是港股18A闸门扩大的又一标志,于小而言,这也标志着劲方医药迈过了一个里程碑,迈入了一个新阶段。在新股发行阶段,它也被资金抢得火热。那么劲方医药,这家在KRAS领域深耕的药企,也确实值得我们去仔细拆解。它的天花板是否高,下限是否稳健呢?01KRAS突变与市场劲方医药的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.